Company: SISI
Filing Date: 2025-05-15
Form Type: 8-K/A
Source: 0001641172-25-010437
Chunk: 1

Company: SHINECO, INC.
Filing Date: 2025-05-15
Form: 8-K/A
Chunk 1
---
.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

<div align='center'>Explanatory Note</div>

As previously disclosed in its Current Report on Form 8-K filed with the Securities and Exchange Commission on May 13, 2025 (the “Original Form 8-K”), on May 12, 2025 (the “Closing Date”), Shineco Life Science Group Hong Kong Co., Limited (“Shineco Life Science”), a subsidiary of Shineco, Inc. (the “Company”), closed an acquisition of 75% of the equity interests in FuWang (HK) International Company Limited, a company limited by shares incorporated in Hong Kong (“FuWang (HK)”), pursuant to the stock purchase agreement (the “SPA”) dated March 20, 2025 with Yi Yang, the only shareholder of FuWang (HK) (the “Seller”). On or prior to the Closing Date, the closing conditions as set forth in the SPA were satisfied or otherwise waived by the parties thereto, and the Seller has transferred 75% of the equity interests in FuWang (HK) to Shineco Life Science; therefore, FuWang (HK) became a direct subsidiary of Shineco Life Science.

This Amendment to the Original Form 8-K is being filed to amend and supplement the Original Form 8-K, the sole purpose of which is to provide the financial statements required by Item 9.01(a), which were excluded from the Original Form 8-K and are filed as exhibits hereto and are incorporated herein by reference. All other items in the Original Form 8-K remain the same.

| 2 |

Item 9.01 Financial Statements and Exhibits

(a) Financial Statements of Businesses Acquired

The audited financial statements of FuWang (HK), which comprise the balance sheets as of June 30, 2024 and 2023, the related statements of operations, shareholders’ equity, and cash flows for the fiscal years ended June 30, 2024 and 2023, and the related notes to the audited financial statements, and the unaudited